---
schema_version: "1.0.0"
document_id: "94b60c864dfbe7adace06238bd4a4c43ccf027d7ac3bd159ef6125bf8a202e3e"
company_key: "yc-glass-health"
company: "Glass Health"
source_id: "yc-glass-health-news-import-5021dfc91ecf"
canonical_url: "https://glass.health/resources/ai-evidence-based-medicine"
published_at: null
first_seen_at: "2026-08-09T22:41:21.143594+00:00"
fetched_at: "2026-08-09T22:41:22.527486+00:00"
content_hash: "sha256:d95ce3e6bc93c62dbaffa0c1676b44970c4d6457b2e38a1bd1ee57872523cb07"
---

# AI for Evidence-Based Medicine 2026 — Clinical Q&A Guide

AI for evidence-based medicine in 2026 means clinical AI tools that ground reasoning, recommendations, and documentation in verifiable medical literature, clinical practice guidelines, and FDA-approved drug information with citations clinicians can inspect. Glass Health combines ambient scribing with evidence-cited differential diagnosis, clinical Q&A, and assessment-and-plan drafting in one platform.


*By Dereck Paul, MD*


## What "AI for evidence-based medicine" means in 2026


Clinical AI should help clinicians retrieve, inspect, and apply evidence without replacing clinical judgment. That is the practical frame for AI in evidence-based medicine in 2026.


The core question is no longer whether a model can produce fluent text. Many systems can. The more useful question is whether a clinician can inspect the reasoning path behind the output. If an AI system suggests a diagnosis, summarizes management options, drafts an assessment and plan, or helps with medication review, the clinician should be able to see the source trail behind those statements and decide whether the evidence fits the patient in front of them.


For most real-world workflows, the relevant source classes are familiar:


- indexed medical literature and citation records from[PubMed](https://pubmed.ncbi.nlm.nih.gov/about/)
- current guidance from organizations such as the[USPSTF](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-a-and-b-recommendations) and[NICE](https://www.nice.org.uk/guidance)
- approved prescribing information from[Drugs@FDA](https://www.accessdata.fda.gov/scripts/cder/daf/)


What has changed is **where** that retrieval can happen. In many care settings, clinicians still move between the chart, a reference tool, and the note they are building. Evidence-based clinical AI is most useful when it shortens that loop. Instead of asking the user to search elsewhere and manually stitch the result back into the encounter, the software can surface literature-grounded answers and draft text while the clinical context is still active.


That distinction matters because speed without provenance is not enough. A plausible answer that cannot be checked is still a review burden. A draft plan that sounds right but does not show its source path still leaves the physician doing the hardest part alone: deciding whether the recommendation is current, applicable, and safe.


In practice, evidence-based AI should make clinical output **inspectable** . If a statement is material to care, the clinician should be able to answer basic questions quickly: What source supports this? Is it a guideline, a primary literature citation, or approved labeling? Is the recommendation framed at the level of evidence that the question requires? Does it apply to this patient population, in this setting, with these constraints?


This is also why evidence-based AI is broader than literature search alone. Search retrieves. Good clinical AI should help retrieve, organize, reason, and draft — while leaving the final decision to the clinician. The point is not to automate judgment. The point is to reduce the time between a clinical question and a verifiable answer.


When people search for evidence-based medicine AI, what they usually want is not a chatbot that sounds medical. They want a workflow that helps them move from patient context to source-backed reasoning to documentation without losing visibility into the evidence. That is the standard worth using in 2026.


## The four pillars of AI EBM


A practical way to evaluate AI for evidence-based medicine is to look for four pillars.


### 1. Guideline-grounded reasoning


The first pillar is reasoning anchored in current guidance. Many day-to-day clinical decisions should connect to guideline-level recommendations, not only to model memory or isolated paper retrieval. In practical terms, that means the AI should help the clinician trace a recommendation to sources such as[USPSTF recommendations](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-a-and-b-recommendations) or[NICE guidance](https://www.nice.org.uk/guidance) .


That matters because guidelines do more than restate facts. They encode thresholds, risk-benefit tradeoffs, implementation recommendations, and evidence review. The USPSTF explains that A and B grade recommendations are services the Task Force most highly recommends implementing. NICE describes its content as evidence-based recommendations developed by independent committees. Those are the kinds of synthesis layers clinicians often need at the point of care.


A model that can point the user toward the relevant guideline is more useful than one that simply states a conclusion. It allows the physician to check recency, population fit, and operational details before acting.


### 2. Primary-literature citations close to each material clinical assertion


The second pillar is statement-level source transparency. If the AI says that a trial changed practice, that a finding supports a diagnosis, or that an intervention has outcome evidence behind it, the supporting citation should be visible near that claim. A bibliography at the bottom is less useful than inline or near-inline citations because it forces the user to reconstruct what supports what.


This is where[PubMed](https://pubmed.ncbi.nlm.nih.gov/about/) remains central. PubMed states that it contains more than 40 million citations and abstracts of biomedical literature. For clinicians, that makes it a practical review layer for checking the literature behind an answer. Even when the AI has already summarized the source, the ability to follow the citation matters.


Inspectability changes how generated text is used. Without visible citations, a clinician is left evaluating style and plausibility. With visible citations, the clinician can review provenance. That is what turns fluent output into something closer to usable clinical decision support.


### 3. FDA-approved drug information for prescribing


Prescribing support should meet a higher source standard than generic web text. If AI touches medication selection, dosing, contraindications, warnings, formulation details, or administration questions, the workflow should connect to authoritative drug information such as[Drugs@FDA](https://www.accessdata.fda.gov/scripts/cder/daf/) .


Drugs@FDA states that it includes information about drugs approved for human use in the United States and, for prescription brand-name drugs, typically includes the most recent labeling approved by the FDA. That makes it especially relevant when the user needs label-based information rather than a generalized summary.


This does not mean AI should prescribe autonomously. It means the software should help the clinician verify the approved information that matters to the decision in front of them. In evidence-based medicine, source hierarchy matters. Guideline recommendations, literature citations, and approved labeling answer different questions, and a strong prescribing workflow respects that difference.


### 4. Clinical question answering with verifiable sources


The fourth pillar is rapid clinical Q&A with sources visible in the answer itself. Physicians do not always need a full note draft or a formal differential. Sometimes they need a fast answer to a focused question: the role of a test, the management implication of a finding, the reason for a recommendation, or the source behind a dosing constraint.


A credible evidence-based AI tool should answer those questions quickly enough to fit clinical workflow and transparently enough to support review. That means the source should not be hidden behind an extra search step. The answer itself should show the clinician what it relied on.


When all four pillars appear together, AI becomes more than text generation. It becomes retrieval plus reasoning plus drafting support with visible provenance.


## What separates evidence-based AI tools from generic scribes


Many ambient scribes are useful because they reduce clerical burden. Capturing a visit, structuring a note, and saving time on documentation are real benefits. But documentation capture and evidence retrieval are not the same job.


The difference shows up in the scope of help the software provides. The Glass Health resource on[the best AI medical scribe](https://glass.health/resources/best-ai-medical-scribe) describes support for real-time clinical Q&A during or after the encounter, grounded in medical literature, guidelines, and drug-reference material. That points to the extra layer evidence-based AI can add beyond transcription alone.


The first difference is inspectability. A generic scribe may produce a clean note. An evidence-based workflow should also show the clinician where a recommendation or summary came from. If the software proposes part of a plan, supports a diagnosis, or answers a focused question, the user should be able to review the source without starting over elsewhere.


The second difference is workflow continuity. If evidence review happens inside the same workflow as note generation, the clinician can assess the source while the patient context is still fresh. That can reduce context switching and may be easier to adopt than a process that splits documentation, evidence review, and plan drafting across separate tabs or tools.


The third difference is output surface. Documentation-first tools mainly help with note completeness and efficiency. Evidence-based AI can support a wider set of clinical outputs in the same session: consult-style question answering, differential diagnosis, chart summarization, and assessment-and-plan drafting with citations visible in the workflow.


That broader frame is why evidence-based clinical AI matters. Physicians do not only need help writing down what happened. They often need help reviewing evidence, organizing reasoning, and drafting next steps — all while keeping the final decision under clinician control.


If you want more background on documentation-first tooling, Glass Health has a related resource on[the best AI medical scribe](https://glass.health/resources/best-ai-medical-scribe) . For broader category context, we also have a resource on[clinical decision support](https://glass.health/resources/best-clinical-decision-support) .


## Glass Health for evidence-based medicine


Glass Health is relevant here because its product workflow is explicitly organized around **ambient clinical decision support** rather than ambient transcription alone. On the[Ambient CDS page](https://glass.health/for-clinicians#ambient-scribing) , Glass describes a workflow that listens during the encounter, provides diagnostic insights while the clinician is with the patient, and then generates documentation afterward. That is the core architectural point: note capture and clinical reasoning support are presented in the same workflow.


The Glass Health[Features page](https://glass.health/for-clinicians#features) highlights a citation-forward workflow spanning **Consult** , **Differential Diagnosis** , **Assessment & Plan** , **Chart Summarization** , and documentation workflows. For evidence-based medicine, those feature areas map to concrete clinical jobs:


1. **Consult** supports focused clinical Q&A. Glass states that each answer cites current research and consensus guidelines inline.
2. **Differential Diagnosis** structures reasoning. Glass describes categorized output that includes Most Likely conditions, Expanded Differential alternatives, and Can’t Miss diagnoses that should be excluded.
3. **Assessment & Plan** supports plan drafting with provenance. Glass describes inline references linking recommendations to their evidence base.
4. **Chart Summarization** helps condense chart context so the clinician can review key information before or during reasoning.
5. **Documentation workflows** turn the encounter into draft notes after the visit, keeping documentation support in the same product surface.


Used together, those steps support a practical evidence-based loop: review context, refine the differential, ask targeted questions, draft the plan, and complete documentation. A connected workflow can help keep those steps together.


Glass Health also emphasizes source grounding. Its medical scribe resource describes outputs grounded in medical literature, guidelines, and drug-reference material. That matters because real clinical questions often blend multiple source types. A diagnostic question may depend on literature and guideline interpretation. A prescribing question may require guideline context plus approved labeling. A draft plan may need both evidence synthesis and documentation support. Glass Health’s workflow is built around that combination rather than around transcription alone.


Integration details matter too. Glass supports SMART on FHIR-based chart-context workflows for supported EHR environments, with non-Epic workflows confirmed directly with Glass during setup.


For buyers, those details are important because they define workflow boundaries. Glass can use chart context in consult, chart summarization, differential diagnosis, and plan-drafting workflows while the clinician remains responsible for reviewing outputs and taking final chart actions.


It is also worth being explicit about rollout assumptions. Supported Epic, athenahealth, eClinicalWorks, and Elation workflows require the **Max plan** . For athenahealth, eClinicalWorks, and Elation, plan direct SMART on FHIR enablement with Glass and your EHR team. The right question is how the product uses chart context, how clinicians review output, and whether that workflow fits your governance, security, and clinical requirements.


Glass also publishes transparent pricing on the[pricing page](https://glass.health/pricing) : **Lite (free)** , **Starter ($20/month)** , **Pro ($90/month)** , and **Max ($200/month)** . Public pricing matters because it lowers the effort required to run a real pilot. Teams can test whether citation quality, plan drafting, and ambient documentation support are useful before committing to a larger rollout.


If your evaluation lens is, "Can this tool show its work while I am still building my assessment?" Glass is built around that use case. If your lens is, "Can it support more than a transcript?" Glass Health supports a broader workflow: consult, cited differential diagnosis, assessment-and-plan drafting, chart summarization, and documentation in one platform.


For additional category context, Glass Health has resources on[AI medical scribes](https://glass.health/resources/best-ai-medical-scribe) and[clinical decision support](https://glass.health/resources/best-clinical-decision-support) .


Ready to evaluate an evidence-cited workflow?[Start a free Glass account](https://glass.health/pricing) or[compare Glass vs OpenEvidence](https://glass.health/compare/openevidence) .


## OpenEvidence vs Glass for EBM


Comparisons between OpenEvidence and Glass for evidence-based medicine are most useful when they stay focused on workflow rather than on absence-based feature claims.


Glass Health emphasizes an encounter-native workflow that combines ambient scribing with cited differential diagnosis, clinical Q&A, and assessment-and-plan drafting. If your priority is evidence review inside the encounter workflow, Glass keeps those functions in one product.


That gives clinicians a practical evaluation path. Instead of asking only whether a tool can answer a question, test whether it can surface evidence while you are reviewing chart context, forming a differential, and drafting a plan. In Glass, the workflow centers on exactly those steps.


For a side-by-side workflow view, see[Glass vs OpenEvidence](https://glass.health/compare/openevidence) .


## UpToDate Expert AI vs Glass for EBM


Wolters Kluwer presents[UpToDate](https://www.wolterskluwer.com/en/solutions/uptodate) as part of its clinical decision support offering, and the[UpToDate home page](https://www.uptodate.com/home) describes it as industry-leading clinical decision support. For clinicians comparing UpToDate Expert AI vs Glass for evidence-based medicine, the most useful practical distinction from public materials is deployment surface.


Glass is positioned around ambient clinical decision support during the encounter: note capture, cited differential diagnosis, clinical Q&A, assessment-and-plan drafting, chart summarization, and documentation in one workflow. That means the comparison is easiest to understand by asking where you want evidence review to happen. If the goal is to keep evidence, reasoning, and drafting together while the encounter is still unfolding, Glass Health directly supports that combined workflow.


For additional context, see[Glass vs UpToDate](https://glass.health/compare/uptodate) .


## Choosing an evidence-based AI tool — checklist for clinicians


When clinicians evaluate AI for evidence-based medicine, the right checklist is not "Does it generate text?" Most products can do that. The better checklist is "Can I verify the reasoning without slowing myself down?"


Use these questions.


1. **Are citations visible next to the clinical claim?**


Inline or near-inline citations are more useful than a generic reading list. You should be able to tell which source supports which recommendation, not reconstruct the answer afterward. The closer the source is to the claim, the easier it is to review before acting.


1. **Does source coverage include literature, guidelines, and drug information?**


A serious evidence-based workflow should be able to pull from sources like[PubMed](https://pubmed.ncbi.nlm.nih.gov/about/) , current guidance such as[USPSTF](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-a-and-b-recommendations) and[NICE](https://www.nice.org.uk/guidance) , and approved prescribing information from[Drugs@FDA](https://www.accessdata.fda.gov/scripts/cder/daf/) . If a tool only does one of those well, you may still need to leave the workflow for the other two.


1. **Does the evidence appear during the encounter or in a separate workflow?**


This is one of the biggest practical dividers in 2026. A separate reference workflow can still be useful. But evidence review that appears alongside the note or plan can reduce context switching and may be easier to adopt in busy clinical settings.


1. **What clinical outputs does the tool support?**


Some workflows are mostly about question answering. Some are mostly about note generation. Glass Health includes a broader surface: Consult, Differential Diagnosis, Assessment & Plan, Chart Summarization, and documentation workflows. Choose the tool based on the actual job to be done in your clinic, service line, or specialty workflow.


1. **How does EHR integration work?**


Ask what data is available, how clinicians review output, and what the implementation actually enables in practice. For Glass, evaluate the chart-context workflow across Epic, eClinicalWorks, athenahealth, and Elation. For athenahealth, eClinicalWorks, and Elation, plan direct workflow review with Glass and your EHR team.


1. **What are the privacy, governance, and contracting terms?**


Confirm HIPAA posture, whether the vendor will sign a BAA, how PHI is processed, what retention controls exist, and who can access logs or transcripts. Evidence quality matters, but operational governance matters too. A clinically useful tool still has to fit your organization’s security and compliance requirements.


1. **Does the product fit your actual workflow?**


Buyers should look for specifics rather than broad marketing language. Glass supports a citation-forward workflow spanning consult, differential diagnosis, assessment-and-plan drafting, chart summarization, and documentation. That kind of specificity is more useful than a generic claim that a tool works "for medicine."


1. **Is pricing transparent enough to support a real pilot?**


Hidden pricing slows evaluation because it turns a workflow question into a sales-process question. Glass Health lists pricing on the[pricing page](https://glass.health/pricing) : Lite (free), Starter ($20/month), Pro ($90/month), and Max ($200/month). Transparent pricing makes it easier to run a short trial with real cases.


One final recommendation: run a case-based pilot. Test the product on the encounters you actually see, not on abstract prompts. Review not just note quality, but citation quality, source relevance, plan usefulness, and the amount of clinician review required to trust the output.


For Glass specifically, a practical pilot can start small. Pick a narrow set of encounter types, define what chart context you want available, and review how Consult, Differential Diagnosis, Assessment & Plan, and Chart Summarization perform on those cases. Implementation should stay focused on data access, review workflow, and clinician adoption rather than abstract integration labels.


If you want deeper category context, Glass also publishes resources on[the best AI medical scribe](https://glass.health/resources/best-ai-medical-scribe) and[clinical decision support](https://glass.health/resources/best-clinical-decision-support) .


## FAQ


### What is AI for evidence-based medicine?


AI for evidence-based medicine is clinical AI that grounds output in verifiable sources rather than model fluency alone. In practice, that means answers or drafted plans tied to sources such as[PubMed](https://pubmed.ncbi.nlm.nih.gov/about/) , current guideline pages like[USPSTF](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-a-and-b-recommendations) and[NICE](https://www.nice.org.uk/guidance) , and approved prescribing information from[Drugs@FDA](https://www.accessdata.fda.gov/scripts/cder/daf/) . The clinician still has to review whether the source fits the patient, setting, and decision at hand.


### Which AI tools cite peer-reviewed medical literature?


The useful test is not the product label. It is whether the workflow shows verifiable sources next to the clinical output. Glass provides evidence-cited differential diagnosis, clinical Q&A, and assessment-and-plan drafting in workflow, and the Glass medical scribe resource describes real-time Q&A grounded in medical literature, guidelines, and drug-reference material.


### Does Glass Health cite primary sources in clinical recommendations?


Glass Health describes an evidence-cited workflow for differential diagnosis, clinical Q&A, and assessment-and-plan drafting ([Ambient CDS](https://glass.health/for-clinicians#ambient-scribing) ,[Features](https://glass.health/for-clinicians#features) ). Glass also states that Consult answers cite current research and consensus guidelines inline, and that Assessment & Plan includes inline references linking recommendations to their evidence base.


### How is OpenEvidence different from Glass Health?


A practical way to approach the comparison is to focus on what Glass does. Glass is positioned around ambient clinical decision support during the encounter, combining ambient scribing with cited differential diagnosis, clinical Q&A, and assessment-and-plan drafting ([Ambient CDS](https://glass.health/for-clinicians#ambient-scribing) ,[Features](https://glass.health/for-clinicians#features) ). See[Glass vs OpenEvidence](https://glass.health/compare/openevidence) for workflow context.


### How is UpToDate Expert AI different from Glass Health?


Wolters Kluwer presents[UpToDate](https://www.wolterskluwer.com/en/solutions/uptodate) as clinical decision support, and Glass is positioned around encounter-native ambient CDS and evidence-cited drafting during note creation and plan formation ([Ambient CDS](https://glass.health/for-clinicians#ambient-scribing) ,[Features](https://glass.health/for-clinicians#features) ). See[Glass vs UpToDate](https://glass.health/compare/uptodate) for additional context.


### Can AI assist with prescribing using FDA drug information?


Yes — as clinician-reviewed decision support. A well-designed workflow can surface approved drug information, label-based details, and supporting evidence to help the clinician verify a prescribing decision. The authoritative public source for approved drug information is[Drugs@FDA](https://www.accessdata.fda.gov/scripts/cder/daf/) . The physician still has to confirm patient-specific appropriateness, formulary constraints, and the final order.


### Is evidence-based AI safe to use in patient care?


It can be useful when deployed as clinician-reviewed decision support rather than autonomous decision-making. Source visibility improves safety because the clinician can inspect the literature, guideline, or drug information behind the recommendation. But citations are necessary, not sufficient. Clinicians should still verify applicability, confirm local policy, and use their own judgment before acting on an AI-generated suggestion.


### What does Glass Health cost?


Glass Health lists pricing at[glass.health/pricing](https://glass.health/pricing) . At the time this guide was reviewed, Glass listed **Lite (free)** , **Starter ($20/month)** , **Pro ($90/month)** , and **Max ($200/month)** .


**Ready to test an evidence-cited workflow?**[Start free Glass account](https://glass.health/pricing) or[Compare Glass vs OpenEvidence](https://glass.health/compare/openevidence) .


Glass Health combines evidence-cited reasoning with ambient scribing in one platform.
